Iantrek launched AlloFlo Uveo, a bio-interventional surgical treatment that targets the uveoscleral pathway in patients with glaucoma, according to a press release.
“Over the past 15 years, glaucoma surgeons have seen dozens of technologies become available for enhancing the trabecular outflow pathway,” Adam Szaronos, CEO of Iantrek, told Healio. “But as we all know, the eye has two natural outflow pathways. This is where the biggest unmet need is and is a complementary fit for every MIGS patient as efficacy inevitably wanes. AlloFlo Uveo provides a reproducible way to access the uveoscleral